ClinicalTrials.gg
RecruitingNCT07315360Updated May 12, 2026

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

A Phase 1 interventional study of PF-07328948 in Renal Impairment and Healthy, sponsored by Pfizer. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Planned enrollment
20th of 36
28 · median 30
Started
2026
with 2 others
Phase 1
23 of 37
2 open now
Registered
36th of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 20th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2026, is one of 23 in phase 1, and was the 36th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn how the study medicine PF-07328948 is processed by the body and how safe and tolerable it is in adults with different levels of kidney function.

The study will include participants who:

  • Are aged 18 to 80 years.
  • Either have normal kidney function or long-term reduced kidney function (moderate or severe).
  • Have a BMI (body mass index) of 17.5 to 40 kilogram per meter squared, inclusive, and a total body weight of more than or equal to 45 kilograms or 99 pounds.

All participants will receive a single dose of PF-07328948 as a tablet taken by mouth. Participants will stay at a clinical research unit for about 6 days to receive the study medicine and undergo safety checks. Total participation lasts up to 64 days, including screening, inpatient stay, and a follow-up call.

The study is not randomized or blinded, meaning all participants and study staff know which treatment is being given. Group assignment is based on kidney function tests done during screening. The results will help researchers understand how reduced kidney function affects the way PF-07328948 works in the body.

03

Conditions studied

  • Renal Impairment
  • Healthy

Browse trials for

Keywords

  • Healthy Volunteers
  • Renal Impairment
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of nonchildbearing potential, between the ages of 18 and 80 years, at the screening visit.
  • of 17.5 to 40.0 kg/m2 (inclusive), and a total body weight ≥45 kg (99 lbs).
  • Stable renal function, defined as ≤25% difference between 2 measurements of .
  • Group 1 only: at screening, no abnormalities identified by a detailed medical history, physical exam, including blood pressure and pulse rate measurement, and clinical laboratory tests.
  • Group 1 only: normal renal function (mean eGFR ≥90 mL/min) based on an average of measures from the screening visits.
  • Groups 2 \& 3 only: good general health considered acceptable with the expected health status of individuals with chronic renal impairment.
  • Groups 2 \& 3 only: chronic renal impairment, defined by the following mean eGFR criteria (based on screening visits):

    • Severe RI: 15 ≤ mean eGFR \<30 mL/min, not requiring hemodialysis.
    • Moderate RI: 30 ≤ mean eGFR \<60 mL/min.

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption.
  • At screening, a positive result for antibodies.
  • History of renal, liver, or heart transplantation.
  • Urinary incontinence without catheterization.
  • Evidence of a prothrombotic state, including history of deep vein thrombosis, pulmonary embolism, or arterial thrombosis, or known genetic predisposition.
  • Use of an product within 30 days or 5 half-lives (whichever longer).
  • A positive urine drug test or breath alcohol test at screening or admission to study clinic.
  • Group 1 only: evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  • Group 1 only: screening demonstrating interval >450 ms or a QRS interval >120 ms.
  • Group 1 only: screening seated systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg
  • Group 2 \& 3 only: presence of acute renal disease
  • Group 2 \& 3 only: requiring dialysis or anticipated need for dialysis
  • Group 2 \& 3 only: listed for solid organ transplantation
  • Groups 2 \& 3 only: persistent severe, uncontrolled hypertension at screening, admission to study clinic, or pre-dose on Day 1.
  • Groups 2 \& 3 only: screening ECG demonstrating a QTcF interval >470 ms or a QRS interval >120 ms.
  • Groups 2 \& 3 only: unstable medical conditions or comorbidities that would interfere with study participation
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Group 1: PF-07328948 participants without renal impairment

    Participants without renal impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet.

    Drug: PF-07328948

  • Experimental
    Group 2: PF-07328948 participants with severe renal impairment

    Participants with severe renal impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet.

    Drug: PF-07328948

  • Experimental
    Group 3: PF-07328948 participants with moderate renal impairment

    Participants with moderate renal impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet.

    Drug: PF-07328948

Interventions

  • PF-07328948 , 1 tablet orally, once on Day 1

06

What researchers measure

Primary outcomes

  1. Fraction of Unbound Drug in Plasma (Fu) of PF-07328948

    Fu is the fraction of unbound drug in plasma, which is calculated by Cu/C (where Cu represents unbound concentration and C represents total concentration).

    Time frame: At 0 (prior to dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose on Day 1

  2. Unbound AUCinf (AUCinf,u) of PF-07328948

    AUCinf is the area under the plasma concentration-time profile from time zero extrapolated to infinite time. AUCinf,u is the unbound AUCinf.

    Time frame: At 0 (prior to dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose on Day 1

  3. Unbound Cmax (Cmax,u) of PF-07328948

    Cmax is the maximum plasma concentration. Cmax,u is the unbound Cmax.

    Time frame: At 0 (prior to dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose on Day 1

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Day 1 to Day 36

07

Study locations

4 of 4 sites recruiting
  • Orange County Research Center
    Lake Forest, California 92630, United States
    Recruiting
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
    Recruiting
  • Genesis Clinical Research, LLC
    Tampa, Florida 33603, United States
    Recruiting
  • Nucleus Network
    Saint Paul, Minnesota 55114, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 13 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 2, 2026
StartActual
Jan 28, 2026
Primary completionEst.
Mar 13, 2027
CompletionEst.
Mar 13, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07315360
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Jan 28, 2026
Primary completion
Mar 13, 2027 (estimated)
Completion
Mar 13, 2027 (estimated)
Last update
May 12, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-07328948

Start the discussion